FAYETTEVILE, N.C. (WTVD) -- Fayetteville native John Rowell calls the FDA's approval of the first injectable treatment for HIV pre-exposure prevention, PrEP, "monumental." The FDA said the injectable ...

Nigerians have begun scrambling for Lenacapavir, a newly introduced injection for the prevention of Human Immunodeficiency ...

According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Add Yahoo as a preferred source to see more of our stories on Google. a group of fit men in blue and white outfits promote national prep day Today is the first National PrEP Day — a new annual event ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Participants Remaining HIV Negative Gilead Launches ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new long-lasting prophylactic treatment for HIV-1 that is administered once every 6 months. Lenacapavir (Yeytuo, Gilead ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. Subscribe to our newsletter for the latest sci-tech news updates. The drug, cabotegravir, would ...